logo-loader
viewRegen Biopharma, Inc.

Regen BioPharma submits revised data package to FDA

The revised application contained preclinical experiments as well as details of the proposed clinical trial.

Cancer cells graphic
Regen said the studies clearly demonstrated its approach was effective.

Regen BioPharma, Inc (OTC:RGBP) has responded to the US Food and Drug Administration (FDA)  with a revised data package supporting its breast cancer immunotherapy.

The revised Investigational New Drug application contained preclinical experiments as well as details of the proposed clinical trial. 

Regen said the results of the studies clearly demonstrated that its enzyme silencing approach was effective at stimulating the type of immune response associated with known checkpoint inhibitors.

Checkpoint inhibitors are the process through which cancer manages to evade detection by the body’s defences.

The proposed dCellVax clinical trial involves generation of patient-specific immune stimulatory cells that are modified to lose expression of a particular immune checkpoint gene. 

Ten patients with advanced breast cancer will be treated in the proposed clinical trial.

“dCellVax is only one of our immune modulatory products that we expect to bring to market in the future.  The data package we sent to the FDA is an important step in this process," said Regen’s chief scientific officer Harry Lander. 

Quick facts: Regen Biopharma, Inc.

Price: 0.00015 USD

OTCMKTS:RGBP
Market: PINK
Market Cap: $85.72 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Protech Home Medical has a full treasury as they look for rapid growth in...

Protech Home Medical (CVE: PTQ- OTCQX: PTQQF) CEO Greg Crawford joined Steve Darling from Proactive to discuss the home medical equipment industry company. That company provides devices like ventilators and oxygen concentrators. Crawford told Proactive the company just completed a large...

2 hours, 37 minutes ago

2 min read